This inventor holds 2 USPTO granted patents. Top assignees: Fonden Til Fremme Af Eksperimental Cancerforskning, Fonden Til Fremme Af Eksperimentel Cancerforskning. Active years: 1995-2001.
Company Filing History:
1 out of 1 
1 out of 1 Years Active: 1995-2001
Title: The Innovative Contributions of Lars S Nielsen
Introduction
Lars S Nielsen is a notable inventor based in Kokkedal, Denmark. He has made significant contributions to the field of cancer research, particularly through his work on monoclonal antibodies. With a total of 2 patents, his innovations have the potential to impact the diagnosis and treatment of tumors.
Latest Patents
Nielsen's latest patents include groundbreaking work on PAI-1 determination and the use of monoclonal antibodies. The first patent focuses on a monoclonal antibody that binds to human endothelial type plasminogen activator inhibitor (PAI-1), which is produced by dexamethasone-treated human HT-1080 fibrosarcoma cells. This antibody can be utilized to determine PAI-1 protein abundance in tumor tissues or body fluid samples. Such measurements may be crucial in predicting tumor presence, metastasis, or the progression of known malignant tumors. The second patent describes a method for producing monoclonal antibodies against endothelial type plasminogen activator inhibitor and similar inhibitors. This method involves fusing myeloma cells with antibody-producing cells from immunized mammals. The resulting hybridomas can be selected for their ability to produce antibodies against the specified inhibitors, which can then be used for various applications, including purification and quantification of plasminogen activator inhibitors.
Career Highlights
Throughout his career, Lars S Nielsen has worked with organizations dedicated to advancing cancer research. Notable among these is the Foundation for the Promotion of Experimental Cancer Research. His work has been instrumental in developing innovative solutions for cancer diagnostics and treatment.
Collaborations
Nielsen has collaborated with esteemed colleagues in the field, including Keld Dano and Peter A Andreasen. These partnerships have contributed to the advancement of research and the development of new therapeutic approaches.
Conclusion
Lars S Nielsen's contributions to cancer research through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in the understanding and treatment of cancer.